WNWannapha Nobnop

Wannapha Nobnop

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wannapha Nobnop has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Outcomes and Prognostic Factors Following Routine CT-Based Image-Guided Adaptive Brachytherapy for Cervical Cancer: A Retrospective Cohort Study

    by Pooriwat Muangwong, Ekkasit Tharavichitkul, Somvilai Chakrabandhu, Pitchayaponne Klunklin, Wimrak Onchan, Bongkot Jia-Mahasap, Piyapasara Toapichattrakul, Wannapha Nobnop, Anirut Watcharawipha, Razvan M. Galalae, et al.

    Background/Objectives: Magnetic resonance imaging (MRI)-based image-guided adaptive brachytherapy (IGABT) is the preferred standard for cervical cancer, but access remains limited in many settings. Computed tomography (CT)-based IGABT provides a practical alternative. We evaluated clinical outcomes and prognostic factors following its routine implementation. Methods: This retrospective cohort study included patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stage I–IVA cervical carcinoma treated with definitive radiotherapy incorporating CT-based IGABT from January 2019 to December 2021. Patients received pelvic external beam radiotherapy (45–50.4 Gy in 23–28 fractions), with or without concurrent platinum-based chemotherapy, followed by four high-dose-rate brachytherapy fractions. Local control and overall survival were estimated using Kaplan–Meier analysis, and prognostic factors were evaluated using Cox regression. Results: Among 237 patients, 56.9% had FIGO stage III–IV disease, and hybrid intracavitary/interstitial brachytherapy was used in 30.2% of fractions. The mean high-risk clinical target volume D90 (HR-CTV D90) was 85.4 ± 2.7 Gy EQD2. Median follow-up was 59.9 months for local control and 71.1 months for overall survival. The 5-year local control and overall survival rates were 84.4% (95% CI, 79.1–88.5%) and 62.9% (95% CI, 56.3–68.8%), respectively. Squamous histology was independently associated with improved local control and overall survival. HR-CTV D90 ≥ 85 Gy EQD2 was associated with improved local control, whereas ≥4 chemotherapy cycles and overall treatment time ≤ 56 days were associated with improved overall survival. Conclusions: Routine CT-based IGABT achieved clinically meaningful outcomes despite the high proportion of advanced-stage disease. Achieving HR-CTV D90 ≥ 85 Gy EQD2, delivering ≥4 chemotherapy cycles, and completing treatment within 56 days were associated with improved outcomes.

  • Assessment of imaging radiation dose from tomotherapy systems

    by Pratchayakan Hompeng, Wannapha Nobnop, Tinnagorn Donmoon, Komkrit Krongkietlearts, Kananan Utitsarn, Sumalee Yabsantia, Thunyarat Chusin

    Background: Tomotherapy systems employ image-guided radiotherapy (IGRT) using either megavoltage (MVCT) or kilovoltage (kVCT) computed tomography for daily patient positioning verification. However, these imaging procedures can deliver a non-negligible radiation dose to the patient. According to the American Association of Physicists in Medicine (AAPM) Task Group 180, this dose should be incorporated into the prescribed treatment dose if it exceeds 5%. Objectives: This study aimed to assess IGRT imaging doses and determine whether the cumulative dose exceeded 5% of the prescribed treatment dose. Materials and methods: Imaging doses from IGRT were evaluated under clinical scan protocols across four tomotherapy machines at three centers, including two MVCT systems and two kVCT systems. Doses were measured as Weighted Multiple Slice Average Dose (MSADw) using a CTDI phantom. Cumulative imaging dose was calculated by multiplying MSADw by the number of imaging sessions, then compared to the prescribed dose for each patient. Results: The mean MSADw values for MVCT ranged from 0.85 to 0.86 cGy per scan, while for kVCT it ranged from 0.19 to 2.65 cGy per scan. Over the treatment course, cumulative imaging doses accounted for 0.34-0.44% of the prescribed dose for MVCT and 0.28-0.87% for kVCT. Notable inter-center variations were observed, with differences of up to 51.16% in breast cancer cases and 35.71% in prostate cancer cases. Conclusion: Cumulative imaging doses from both MVCT and kVCT across all centers remained below the 5% threshold, indicating no need to adjust the prescribed dose in clinical practice. Nevertheless, further studies are required to identify the causes of inter-center variations and to develop optimized imaging protocols aimed at minimizing patient dose while maintaining adequate image quality.

  • Open Access

    Phantom-Based Dosimetric Comparison of Helical and Fixed-Beam TomoTherapy for Spatially Fractionated Radiotherapy Using GRID and Lattice Target Designs

    by Narakorn Sihawong, Wannapha Nobnop, Imjai Chitapanarux, Anirut Watcharawipha, Akanit Chaiyapong

    Introduction: Spatially Fractionated Radiotherapy (SFRT) delivers intentionally heterogeneous dose distributions with alternating high- and low-dose regions and has been widely applied in the management of bulky tumors. In SFRT, high-dose sub-volumes (referred to as vertices) are distributed within the gross tumor volume (GTV) to create a spatial peak–valley dose pattern. However, studies of SFRT using the TomoTherapy platform remain limited. This study evaluates the dosimetric performance of GRID and lattice vertex designs using TomoHelical and TomoDirect techniques. Methods: A phantom-based planning study was performed with two simulated GTV representing medium- and large-sized tumors. Cylindrical GRID vertices and spherical lattice vertices were created with diameters of 1.00 cm and 1.25 cm and corresponding center-to-center spacings of 3.0 cm and 2.5 cm, respectively. Treatment plans were created using TomoHelical and TomoDirect techniques with identical prescription criteria, requiring at least 50% of the target volume to receive 15 Gy in a single fraction. Beam-on time, normal tissue dose metrics (V30% and V50%), homogeneity index, conformity index, peak-to-edge dose ratio (PEDR), and peak-to-valley dose ratio (PVDR) were evaluated. Delivery accuracy was assessed using ArcCHECK measurements with a 3%/2 mm gamma criterion. Results: All plans met prescription and delivery accuracy requirements, with gamma passing rates exceeding 95%. TomoHelical produced higher PVDR and PEDR values, improved conformity, and lower V50% compared with TomoDirect. TomoDirect achieved shorter beam-on times but showed greater variability in vertex mean dose. Lattice configurations yielded higher PVDR values than GRID, while vertex diameter had minimal impact on most dosimetric parameters. Conclusion: TomoHelical delivery combined with lattice designs provided superior dose modulation and normal tissue sparing for SFRT, while requiring longer delivery times. In contrast, GRID designs enabled faster treatment delivery. These findings provide practical guidance for optimizing SFRT planning using the TomoTherapy platform.


  • Open Access

    Comparative evaluation of image‐guided radiation therapy (IGRT)‐based dose calculation accuracy using cone‐beam, megavoltage, and kilovoltage CT modalities

    by Sirawit Saobai, Anirut Watcharawipha, Somsak Wanwilairat, Warit Thongsuk, Wannapha Nobnop

    Purpose: This study evaluates the dosimetric accuracy of three image‐guided radiotherapy (IGRT) imaging modalities, cone‐beam computed tomography (CBCT), megavoltage computed tomography (MVCT), and image‐guided kilovoltage computed tomography (IG‐kVCT), using modality‐specific HU‐to‐density (HU‐D) calibrations. Dose calculations from IGRT images were compared to computed tomography simulation (CT‐sim) references in phantoms and validated against measurements from head and neck and prostate patient plans to assess the feasibility of each modality for precise dose calculation in adaptive radiotherapy (ART). Methods: Two phantoms, the Tomo phantom HE and CIRS Thorax phantom, were used for HU‐to‐density (HU‐D) calibration. IGRT images were acquired using Elekta Synergy XVI (CBCT) and Radixact X9 (MVCT and IG‐kVCT), and calibration curves were generated for each modality. Dose distributions calculated from IGRT images were then compared with those from CT‐sim in phantom studies. For measurement‐based evaluation, 10 patient plans (head and neck and prostate cases) were delivered to a phantom and measured using the ArcCHECK system, and recalculated doses on CT‐sim and IGRT images were compared to the measured doses. Gamma analysis was performed to assess dosimetric accuracy. Results: IG‐kVCT showed the closest agreement with CT‐sim, achieving gamma passing rates (GPR) of 99.8% ± 0.3% for 3%/3 mm and 98.5% ± 0.7% for 3%/2 mm criteria, with dose differences below 1%. CBCT and MVCT demonstrated slightly lower accuracy, with GPRs of 97.2% ± 1.1% and 96.5% ± 1.3% for 3%/3 mm, respectively, and dose differences up to 2%. Similar trends were observed when compared to measured doses. All IGRT modalities showed clinically acceptable agreement, and no statistically significant differences were found between CT‐sim and any IGRT modality. Conclusion: All three IGRT modalities demonstrated clinically acceptable accuracy for adaptive dose calculation with modality‐specific HU‐D calibration curves.


  • Open Access

    Normal cell responses to 3D-CRT, VMAT, and helical tomotherapy: A comparative study

    by Rinwarat Phumsankhot, Phanwadee Kasetthamrongrat, Aphidet Duangya, Anirut Watcharawipha, Wannapha Nobnop, Narongchai Autsavapromporn


  • Open Access

    Impact of patient transfer system on applicator stability and dosimetry in cervical cancer brachytherapy

    by Jittima Junhong, Ekkasit Tharavichitkul, Anirut Watcharawipha, Somsak Wanwilairat, Wannapha Nobnop

    This study aimed to evaluate applicator displacement due to patient transfer using traditional fixation (TRD) with and without patient transfer system (TS), and to assess its dosimetric impact on organs at risk (OARs). Computed tomography (CT) images, including high-risk clinical target volume (HR-CTV) and OARs structures, were analyzed from 46 treatment plans involving 32 patients undergoing intracavitary brachytherapy with tandem-ovoid applicator, using either traditional fixation (TRD) alone or in combination with patient transfer system (TRD + TS). Applicator displacement was assessed by measuring the distance between applicator base in two sets of CT images: one acquired during treatment planning (pre-plan), and second at dose delivery (pre-load). Dosimetric impact was evaluated for each simulated applicator shift. The use of TRD + TS resulted in reduced applicator displacement compared with TRD alone. The mean magnitude of displacement decreased from 2.94 mm to 1.43 mm laterally, from 3.17 mm to 1.83 mm in the anterior-posterior direction, and from 3.45 mm to 2.00 mm longitudinally. Regarding dose variations to D2cc for the bladder, rectum, sigmoid, and bowel, the average dose increases were 0.54%, 8.39%, 3.78%, and 0.58% for TRD, and 3.19%, 1.66%, 2.83%, and 1.19% for TRD + TS, respectively. No statistically significant difference was observed in either applicator displacement or radiation dose to OAR between the two systems. The combination of traditional fixation and patient transfer system have the potential to reduce applicator displacement, thereby enhancing treatment accuracy. However, in this study, no statistically significant difference was observed when compared with our traditional fixation method.


  • Open Access

    Comparison of Tumor Cell Responses to Different Radiotherapy Techniques: Three-Dimensional Conformal Radiotherapy (3D-CRT), Volumetric Modulated Arc Therapy (VMAT), and Helical Tomotherapy (HT)

    by Phanwadee Kasetthamrongrat, Rinwarat Phumsankhot, Aphidet Duangya, Anirut Watcharawipha, Wannapha Nobnop, Narongchai Autsavapromporn

    Currently, advanced RT techniques such as VMAT and HT are being developed to optimize tumor coverage while minimizing radiation exposure to the surrounding organs that are at risk. Despite their growing clinical use, comparative studies evaluating the dosimetric and radiobiological effects of these modalities remain limited. In this study, A549, HeLa, and HepG2 cells were exposed to a single 2 Gy dose, using three RT techniques (3D-CRT, dual arc VMAT, and HT). Treatment plans were generated using a water phantom to ensure consistent target coverage and comparable dosimetric parameters across the techniques. Multiple radiobiological endpoints were assessed to evaluate the cellular responses. Although all three techniques yielded similar dosimetric parameters without statistically significant differences, the biological responses varied among the cell lines. Notably, VMAT and HT demonstrated superior tumor cell suppression compared to 3D-CRT. This was likely due to their enhanced dose conformity and modulation precision, which potentially led to improved tumor cell killing. These findings highlight the importance of integrating radiobiological assessments with physical dose metrics to inform the clinical application of advanced RT technologies. However, this study had several limitations. The use of a single radiation dose limited its clinical relevance, and the immediate post-irradiation assessments may not have captured delayed biological responses. Additionally, the small number of replicates may have reduced the study’s statistical power. Future studies incorporating dose fractionation schemes, time course analyses, and larger sample sizes are warranted to better simulate clinical conditions and further elucidate the radiobiological effects of advanced RT techniques.


  • Open Access

    Feasibility of Large Multi-Leaf Collimator in Stereotactic Radiosurgery/Stereotactic Radiotherapy: A Single Center Experience

    by Akanit Chaiyapong, Anirut Watcharawipha, Wannapha Nobnop, Anupong Kongsa, Bongkot Jia-Mahasap

    OBJECTIVE This study investigated the feasibility of using a large multi- leaf collimator (MLC) in a C-arm based linear accelerator for stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT). METHODS Patient Specific Quality Assurance was conducted on 69 patients treated with a single lesion SRS/SRT measuring dose distribution using patient-specific plans with SRS MapCHECK®. Statistics were used to analyze the significance of correlation among dosimetric parameters, included Conformity Index (CI), Gradient Index (GI), plan complexity, and Gamma passing rate (GPR) in an absolute dose (AD) and relative dose (RD). confidence limit (CL) was also calculated to evaluate the performance of a large multileaf collimator (MLC) in SRS/SRT. RESULTS Planning target volumes (PTVs) ranged between 0.34 cm3 and 30.42 cm3. The study found a value of CIICRU, CIPaddick, and GI of 1.29 ± 0.17, 0.77±0.10 and 5.24±2.18 (mean±SD), respectively, significant correlations were found between PTV sizes and dosimetric parameters. Values of GPR2%/2mm were 92.42±3.74 (AD), 96.38±3.24 (RD), whereas GPR2%/1mm were 82.03±6.69 (AD), 89.64±7.26 (RD). No significant correlation was found between plan complexity and GPR. CL values were 85.09% (AD), 90.03% (RD) for GPR2%/2mm and 68.92% (AD), 75.41% (RD) for GPR2%/1mm. CONCLUSIONS This study assessed the feasibility of using a large MLC for a single lesion SRS/SRT across various PTV sizes. The values of CI and GI decreased for a small lesion. While the large MLC performed adequately across different PTV sizes, the CL value of RD GPR at 2%/1 mm fell below 90%. This indicates that the contribution of PTV margin might be consi-dered for a large MLC in SRS/SRT. KEYWORDS stereotactic radiosurgery, stereotactic radiotherapy, multi- leaf collimator, dosimetric parameter, gamma analysis

  • Open Access

    Verification of daily dose recalculation accuracy for an adaptive radiation therapy monitoring tool in helical tomotherapy for nasopharyngeal carcinoma

    by Yawitta Maneepan, Anirut Watcharawipha, Imjai Chitapanarux, Somsak Wanwilairat, Wannapha Nobnop

    Purpose: PreciseART, an adaptive radiation therapy (ART) software for helical tomotherapy (HT), was integrated into the Precision treatment planning system (Accuray, Inc., Sunnyvale, CA). It supports automatic monitoring of dose variations to both the target and organs at risk (OARs) throughout the treatment course. This study aims to verify the accuracy of PreciseART's automatic dose recalculation and assess the effectiveness of its notification function.Methods: The Radixact X9's kVCT image‐guided system (ClearRT) was used to acquire daily images for dose recalculations. We assessed the accuracy of PreciseART's automatic dose recalculation by comparing it with the treatment planning system (TPS) recalculation for the PTV70, spinal cord, and bilateral parotid glands. We also evaluated the efficacy of its notification function by comparing each dose metric for each notification color to TPS recalculation, assessing its role as a trigger tool.Results: In the phantom study, dosimetric analysis indicated no statistically significant differences between TPS and PreciseART recalculations (p > 0.05), with dose variations under 1.5%. Similarly, in the patient study (n = 10), no significant dosimetric discrepancies were found (p > 0.05), with a maximum variation of 2.3%. The notification system performed effectively, providing accurate notifications in accordance with predefined dose criteria.Conclusions: PreciseART's daily dose recalculation demonstrated good agreement with TPS recalculation, and its notification function is effective for identifying dose threshold compliance, supporting its use in clinical ART.